Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - Compugen reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, and compared to a loss of $0.02 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $1.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 76.15%, and a significant drop from year-ago revenues of $6.7 million [2] - Compugen has not surpassed consensus EPS estimates over the last four quarters, indicating ongoing challenges in meeting market expectations [2] Stock Outlook - Compugen shares have lost about 4.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1%, highlighting underperformance relative to the broader market [3] - The current consensus EPS estimate for the coming quarter is -$0.07 on revenues of $5.47 million, and for the current fiscal year, it is -$0.28 on revenues of $14.78 million, suggesting continued struggles ahead [7] Industry Context - Compugen operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, indicating a challenging environment for growth [8] - The performance of Compugen's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]